In the TIL compartment, B16 melanomas treated with ADU-S100 + anti-ISG15 (vs. ADU-S100 alone) displayed a significant decrease in total CD8+ TIL content, but these T cells were enriched in the CD8+CD69+ activated phenotype (Figure 6C). Here, CD8A is linked to melanoma.